Skip to main content

Table 1 Clinical characteristics and IVF-ET data

From: The clinical outcome of Dienogest treatment followed by in vitro fertilization and embryo transfer in infertile women with endometriosis

 

Control

DNG

p

Patients (n)

34

30

 

Age (years)

33.6 ± 3.6

34.2 ± 3.4

ns

Stage of endometriosis rASRM (III)

9

10

 

rASRM (IV)

5

6

 

Serum CA125 (U/ml) (before DNG)

–

44.2 ± 35.3

 

Serum CA125 (U/ml)

26.4 ± 16.8

29.1 ± 26.9

ns

Gonadotropin (FSH/HMG) dose (IU)

1304 ± 338

1553 ± 528

P < 0.05

Estradiol (pg/ml)

1731 ± 958

1288 ± 1091

P < 0.05

Progesterone (ng/ml)

1.11 ± 1.14

1.72 ± 2.0

ns

Follicles ≥15 mm (n)

6.5 ± 4.2

4.6 ± 3.2

P < 0.05

  1. IVF-ET In vitro fertilization and embryo transfer, DNG Dienogest